Search research articles
Contact Us
Filters
Showing results (31-40 of 39) with videos related to
Page
of 4
Sort By:
You have reached the last page of results.
This site can display upto 39 results.
Journal of Medicinal Chemistry
|
August 1, 1983
Ultra-short-acting beta-adrenergic receptor blocking agents. 3. Ethylenediamine derivatives of (aryloxy)propanolamines having esters on the aryl function
P W Erhardt, C M Woo, W L Matier, et al.
Cardiovascular Research
|
July 1, 1981
Effects of propranolol on myocardial infarct size with and without coronary artery reperfusion in the dog
R D Reynolds, W E Burmeister, R J Gorczynski, et al.
Toxicology and Applied Pharmacology
|
December 1, 1987
Cardiovascular effects of chronic high-dose atriopeptin III infusion in normotensive rats
E G Spokas, O D Suleymanov, S E Bittner, et al.
Circulation
|
December 1, 1989
Prevention of reoccluding platelet-rich thrombi in canine femoral arteries with a novel peptide antagonist of platelet glycoprotein IIb/IIIa receptors
E J Haskel, S P Adams, L P Feigen, et al.
Life Sciences
|
August 30, 1982
Ultra-short acting beta-blockers: a proposal for the treatment of the critically ill patient
J Zaroslinski, R J Borgman, J P O'Donnell, et al.
Journal of Medicinal Chemistry
|
August 1, 1984
[(Arylcarbonyl)oxy]propanolamines. 1. Novel beta-blockers with ultrashort duration of action
S T Kam, W L Matier, K X Mai, et al.
Thrombosis Research
|
June 1, 1991
In vitro and in vivo effects of a peptide mimetic (SC-47643) of RGD as an antiplatelet and antithrombotic agent
N S Nicholson, S G Panzer-Knodle, A K Salyers, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
March 1, 1991
Antiplatelet and antithrombotic effects of platelet glycoprotein IIb/IIIa (GPIIb/IIIa) inhibition by arginine-glycine-aspartic acid-serine (RGDS) and arginine-glycine-aspartic acid (RGD) (O-me)Y (SC-46749)
N S Nicholson, S G Panzer-Knodle, A K Salyers, et al.
Journal of the American College of Cardiology
|
August 10, 2000
Low-dose enoximone improves exercise capacity in chronic heart failure. Enoximone Study Group
B D Lowes, M Higginbotham, L Petrovich, et al.
Page
of 4
Search research articles
Search
Showing results (31-40 of 39) with videos related to
Sort By:
Page
of 4
You have reached the last page of results.
This site can display upto 39 results.
Journal of Medicinal Chemistry
|
August 1, 1983
Ultra-short-acting beta-adrenergic receptor blocking agents. 3. Ethylenediamine derivatives of (aryloxy)propanolamines having esters on the aryl function
P W Erhardt, C M Woo, W L Matier, et al.
Cardiovascular Research
|
July 1, 1981
Effects of propranolol on myocardial infarct size with and without coronary artery reperfusion in the dog
R D Reynolds, W E Burmeister, R J Gorczynski, et al.
Toxicology and Applied Pharmacology
|
December 1, 1987
Cardiovascular effects of chronic high-dose atriopeptin III infusion in normotensive rats
E G Spokas, O D Suleymanov, S E Bittner, et al.
Circulation
|
December 1, 1989
Prevention of reoccluding platelet-rich thrombi in canine femoral arteries with a novel peptide antagonist of platelet glycoprotein IIb/IIIa receptors
E J Haskel, S P Adams, L P Feigen, et al.
Life Sciences
|
August 30, 1982
Ultra-short acting beta-blockers: a proposal for the treatment of the critically ill patient
J Zaroslinski, R J Borgman, J P O'Donnell, et al.
Journal of Medicinal Chemistry
|
August 1, 1984
[(Arylcarbonyl)oxy]propanolamines. 1. Novel beta-blockers with ultrashort duration of action
S T Kam, W L Matier, K X Mai, et al.
Thrombosis Research
|
June 1, 1991
In vitro and in vivo effects of a peptide mimetic (SC-47643) of RGD as an antiplatelet and antithrombotic agent
N S Nicholson, S G Panzer-Knodle, A K Salyers, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
March 1, 1991
Antiplatelet and antithrombotic effects of platelet glycoprotein IIb/IIIa (GPIIb/IIIa) inhibition by arginine-glycine-aspartic acid-serine (RGDS) and arginine-glycine-aspartic acid (RGD) (O-me)Y (SC-46749)
N S Nicholson, S G Panzer-Knodle, A K Salyers, et al.
Journal of the American College of Cardiology
|
August 10, 2000
Low-dose enoximone improves exercise capacity in chronic heart failure. Enoximone Study Group
B D Lowes, M Higginbotham, L Petrovich, et al.
Page
of 4